Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vanguard Value Index Fund ETF (VTV) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

VTV (Vanguard Value ETF) trades at $219.20, up 0.29% with a bullish technical signal from moving averages. The ETF has gained 16% year-to-date and 27% over the past year, benefiting from investor rotation away from technology stocks toward value-oriented large caps. Recent news highlights VTV's defensive positioning with only 13% technology exposure and a focus on stable dividend-paying companies.

The outlook remains positive as value stocks continue their momentum amid AI sector concerns and potential Fed rate hikes. Key risks include macroeconomic sensitivity and sector rotation reversals. The ETF's low 0.03% expense ratio and higher dividend yield compared to broad market alternatives provide competitive advantages for long-term investors.